June 17, 2022
Read our new published article in Frontiers in Oncology about new and advanced approach for identification of new targets and mechanisms driving drug resistance in melanoma. Congratulations to the team! https://pubmed.ncbi.nlm.nih.gov/35785205/

March 2, 2022
Read our new published review in American Journal of Cell-Physiology about regulation and targeting of ECM for cancer therapy. https://pubmed.ncbi.nlm.nih.gov/35235427/

February 3, 2022
In our new published review in Trends in Cancer provide an overview of the transcriptional mechanisms that drive the response and resistance to immunotherapies. We also discuss possible interventions to enhance the outcomes of immunotherapies by targeting dysregulated transcriptional networks in cancer cells. https://pubmed.ncbi.nlm.nih.gov/35125331

January 11, 2022
Congratulations to Dr. Gupta for receiving highly prestigious UAB Pittman’s Scholars award. https://www.uab.edu/medicine/news/latest/item/2476-2022-pittman-scholars

October 26, 2021
We are thrilled to share our new work identifying TP-472 as a potentially useful therapeutic agent for melanoma therapy published in Cancers journal.
https://www.mdpi.com/2072-6694/13/21/5516

September 16, 2021
Epigenetic factors drive drug resistance and have direct implications for the prevention and treatment of drug-resistant cancer. To know more read our new review published in Cancer Research journal.
https://pubmed.ncbi.nlm.nih.gov/34531319/

July 20, 2021
Lab receives prestigious, five-year $1.63 million R01 grant from the NCI/NIH to support our research work on breast cancer!

July 12, 2021
Congratulations to team for the excellent study published in Oncogenesis journal showing the role of epigenetic modifier DOT1L in ovarian cancer. Our study was widely covered at various science news sites and was one of the most read article!
https://pubmed.ncbi.nlm.nih.gov/34253709/
https://www.uab.edu/news/research/item/12197-ovarian-cancer-potential-therapeutic-target-identified
https://www.sciencedaily.com/releases/2021/08/210805154731.htm

October 6, 2020
Read our excellent review on Transcriptional regulators and alterations that drive melanoma initiation and progression published in Oncogene journal.
https://pubmed.ncbi.nlm.nih.gov/33024276/

September 1, 2020
We are grateful to receive funding from Department of defense (DoD) FY19 Idea Award with Special Focus to support our research work!

August 28, 2020
Our collaborative study with Wajapeyee lab identifies LIMK2 to be an important driver of Triple Negative breast cancer. This study was published in Oncogenesis journal.
https://pubmed.ncbi.nlm.nih.gov/32859889/

June 8, 2020
Our study Identifying Mutational Landscape of Gynecological Malignancies published in Journal of Cancer.
https://pubmed.ncbi.nlm.nih.gov/32626534/

June 2, 2020
Congratulations to Dr. Gupta for her important finding getting published in PNAS
https://pubmed.ncbi.nlm.nih.gov/32430335/

May 20, 2020
Our work revealing the loss of HAT1 confers BRAFV600E inhibitor resistance to melanoma cells by activating MAPK signaling via IGF1R published is online at Oncogenesis journal.
https://pubmed.ncbi.nlm.nih.gov/32371878/

March 2, 2020
We are grateful to get the funding from NIH Small Grant Program (R03) for our work on Ovarian Cancer.

June 15, 2019
The Gupta Lab opens at the University of Alabama at Birmingham!